Investigating the role of pharmacogenomics in optimizing pediatric medication therapy: a pilot study

The Food and Medication Organization and the Public Establishments of Wellbeing have worked to move pharmacogenomics from the laboratory to the patient's bedside. Pharmacogenomic data is now included on the label of more than 100 pharmaceutical drugs. In the pediatric population, several of these are often utilized. Additionally, medical practitioners must intervene and provide advice regarding direct-to-consumer genetic test kits. Healthcare workers must gain a basic understanding of pharmacogenomics and how it applies to patient care in light of the growing trend toward customized treatment. Because pharmacogenomic testing can provide patient-explicit indicators for medication reaction and security, pharmacologists can effectively participate in clinical understanding of results, pharmacogenomic testing, and ideas for individualizing drug treatment. In both short-term and long-term contexts, drug specialists can identify possible opportunities, such as demonstrating pharmacogenomic testing to patients and their families and supervising the implementation of clinical pharmacogenomics meetings. Pharmacists may work in clinical settings as well as in medication development and discovery that is impacted by genetics. The creation of interprofessional practice guidelines and dosing recommendations for pharmacogenomic testing in pediatric patients should involve pediatric pharmacists because of the possibility that age-dependent and genetic factors would affect drug selection and dosage. The purpose of this pilot project is to investigate how pharmacogenomics can be used to customize prescription regimens for young patients in order to increase effectiveness and lower adverse drug reactions (ADRs).